Health Catalyst reported Q3 2026 results

Item 2.02. Results of Operations and Financial Condition.

On November 5, 2026, Health Catalyst, Inc. (the "Company") issued a press release relating to its financial results for the quarter ended September 30, 2026.^{1 1}A copy of the press release is attached hereto as Exhibit 99.1¹ and is incorporated herein by reference.

The foregoing information (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended², or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No. Description

99.1*³

Health Catalyst, Inc. press release for quarterly financial results, dated November 5 , 2026³

104 Cover page Interactive Data File (embedded within the Inline XBRL document)³

* Furnished herewith.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

HEALTH CATALYST, INC.

Date: November 5, 2026 By: /s/ Jason Alger⁴

Jason Alger⁴

Chief Financial Officer⁴

Health Catalyst Reports Third Quarter 2026 Results

SALT LAKE CITY, UT, November 5, 2026 — Health Catalyst, Inc. ("Health Catalyst," Nasdaq: HCAT), a healthcare intelligence company designed to accelerate measurable improvement for health systems, today reported financial results for the quarter ended September 30, 2026.

"We delivered a third quarter above the high end of our revenue and Adjusted EBITDA guidance, and we are reaffirming our full-year outlook," said Simeon Kohl, President and Chief Executive Officer of Health Catalyst. "Our immediate priority is to strengthen the foundation of the business, with a focus on retaining the clients we serve and developing a path to generating durable, profitable revenue."

Financial Highlights for the Three Months Ended September 30, 2026

Key Financial Metrics

Three Months Ended September 30, Year over Year Change

2026 (2)

2025

GAAP Financial Measures: (in thousands, except percentages, unaudited)

Total revenue $ 56,283 $ 76,323 (26)%⁵

Gross profit⁶

$ 17,345 $ 29,979 (42)%⁶

Gross margin⁶

Non-GAAP Financial Measures: (1)

Adjusted Gross Profit

$ 24,913 $ 40,133 (38)%

Adjusted Gross Margin

________________________

(1) These measures are not calculated in accordance with generally accepted accounting principles in the United States (GAAP). See the accompanying "Non-GAAP Financial Measures" section below for more information about these financial measures, including the limitations of such measures, and for a reconciliation of each measure to the most directly comparable measure calculated in accordance with GAAP.

(2) The net income generated during the three months ended September 30, 2026 was largely driven by a $65.9 million gain on sale of the Vitalware Business⁷, while total revenue, gross profit, gross margin, Adjusted Gross Profit, Adjusted Gross Margin, and Adjusted EBITDA decreased year-over-year primarily as a result of the divestiture of the Vitalware Business on July 31, 2026 and headwinds related to the migration from DOS to Ignite, partially offset by our cost reduction initiatives⁸. See Management's Discussion and Analysis of Financial Condition and Results of Operations for more detail.

Financial Outlook

Health Catalyst provides forward-looking guidance on total revenue, a GAAP measure, and Adjusted EBITDA, a non-GAAP measure.

For the full year of 2026, we expect:¹⁰

• Total revenue of $246 million to $249 million, and¹⁰

• Adjusted EBITDA of $18 million to $18.5 million.¹⁰

We have not provided forward-looking guidance for net income (loss), the most directly comparable GAAP measure to Adjusted EBITDA, and therefore have not reconciled guidance for Adjusted EBITDA to net income (loss), because there are items that may impact net income (loss), including stock-based compensation, that are not within our control or cannot be reasonably forecasted.

Quarterly Conference Call Details

We will host a conference call to review the results today, Thursday, November 5, 2026, at 5:00 p.m. E.T. The conference call can be accessed by dialing (800) 343-5172 for U.S. participants, or (203) 518-9856 for international participants, and referencing conference ID "HCATQ326." A live audio webcast will be available online at https://ir.healthcatalyst.com/. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call, at the same web link, and will remain available for approximately 90 days.

About Health Catalyst

Health Catalyst, Inc. (Nasdaq: HCAT) is a healthcare intelligence company designed to accelerate measurable improvement for health systems across cost, clinical, and consumer performance. Backed by deep domain expertise, proprietary AI-driven technology, and $2.8 billion in documented outcomes, Health Catalyst helps health systems move from data to confident, measurable action.

Available Information

Our investors and others should note that we announce material information to the public about our company, products and services, and other matters related to our company through a variety of means, including our website (https://www.healthcatalyst.com/), our investor relations website (https://ir.healthcatalyst.com/), press releases, SEC filings, public conference calls, and social media, including our LinkedIn (https://www.linkedin.com/company/healthcatalyst) and our CEO's social media accounts such as LinkedIn (https://www.linkedin.com/in/simeon-kohl-224a945/), in order to achieve broad, non-exclusionary distribution of information to the public and to comply with our disclosure obligations under Regulation FD.

Forward-Looking Statements

This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, as amended. These forward-looking statements include statements regarding our future growth, our growth and transformation strategies, our strategic priorities, and our financial outlook for the fourth quarter and full year 2026. Forward-looking statements are subject to risks and uncertainties and are based on potentially inaccurate assumptions that could cause actual results to differ materially f